** Shares of drug maker Marinus Pharmaceuticals down 12.6% at $1.30 before the bell
** Co says its intravenous treatment, for a type of seizure known as refractory status epilepticus, failed to meet one of the two key goals, in a late stage study
** Miranus's drug ganaxolone, a neuroactive steroid, failed to achieve statistical significance on the second endpoint of the proportion of patients not progressing to intravenous anesthesia versus placebo
** The oral version of the drug, under the brand name Ztalmy, is approved by the U.S. FDA for treatment of seizures associated with CDKL5 deficiency disorder, a rare genetic epilepsy
** As of last close, stock down 86.5% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))
Comments